You are here: Industry Insights > Hemophilia

News List

New Breakthrough in the Therapy of Hemophilia: Chinese Recombinant Coagulation Factor VIII has been Approved for Marketing PharmaSources/Yefenghong
August 11, 2021
On July 23, according to latest announcement in the official website of the National Medical Products Administration (NMPA), the recombinant coagulation factor VIII (SCT800) for injection developed by Shenzhou Cell Biotechnology.
Catalyst Receives Fast Track Designation for Hemophilia Episodic Bleeding Treatment americanpharmaceuticalreview
December 03, 2020
Catalyst Biosciences announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously (SQ) administered next-generation engineered coagulation ...
Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy pharmaceutical-business-review
November 25, 2020
Pfizer announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or ...
Early Trial Offers New Hope for People With Hemophilia drugs.com
September 18, 2020
Researchers may have found a way for people with severe hemophilia to take their standard treatment less often, if the results of an early trial pan out.
World Federation of Hemophilia (WFH) publishes "The WFH Guidelines for the Management of Hemophilia, 3rd edition" prnasia
August 04, 2020
Led by content leads, Alok Srivastava, MD, and Glenn Pierce, MD, PhD, WFH Vice-President, Medical, this 3rd edition of the World Federation of Hemophilia (WFH) Guidelines for the Management of Hemophilia offers up-to-date guidance and practical recommenda
WuXi AppTec to Launch a Special Webinar on Collaborations that Transform on July 16 | Advances in Rare Diseases: Hemophilia prnasia
July 09, 2020
As an enabler of the biotech and medical device industry, WuXi AppTec shares the conviction that we must work collaboratively to solve industry-wide problems and bring transformational medicines to people living with rare diseases.
Dr Reddy’s launches generic hemophilia injection in US expresspharma
May 06, 2020
The company has launched desmopressin acetate injection USP, 4 mcg/mL single-dose ampules in the US market, Dr Reddy”s Laboratories said in a filing to the BSE.
FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors americanpharmaceuticalreview
April 06, 2020
The U.S. Food and Drug Administration (FDA) approved Sevenfact [coagulation factor VIIa (recombinant)-jncw].
Gene Therapy May Be Long-Term Cure for Type of Hemophilia drugs
January 03, 2020
A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, early clinical trial results indicate.
Two lots of Kogenate® recalled due to mislabelling europeanpharmaceuticalreview
July 25, 2019
Two lots of Kogenate® FS vials actually contain the FVIII hemophilia A treatment, Jivi®.

Previous page 1 2 3 Next page